Showing results (21-30 of 27) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Structure (London, England : 1993)|September 26, 2024
Discovery and characterization of a pan-betacoronavirus S2-binding antibodyNicole V Johnson, Steven C Wall, Kevin J Kramer, et al.Plos Pathogens|September 18, 2024
Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral familiesMatthew J Vukovich, Andrea R Shiakolas, Jared Lindenberger, et al.The Lancet. Infectious Diseases|October 23, 2022
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trialShabir A Madhi, Gaurav Kwatra, Simone I Richardson, et al.Cell Reports|January 28, 2023
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donorKelsey A Pilewski, Steven Wall, Simone I Richardson, et al.Journal of Virology|November 10, 2025
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivityParker J Jamieson, Xiaoying Shen, Alexandra A Abu-Shmais, et al.Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.PLOS Global Public Health|April 11, 2024
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.Pageof 3